Alzheimer’s Research UK’s new Data Discovery Award offers up to £100,000 for ambitious, data-driven dementia research, and gives successful teams early access to the UKB-PRISM proteomics dataset before it is released publicly.
UKB-PRISM is a collaboration between UK Biobank, Alamar Biosciences and Nightingale Health, funded by LifeArc and the Michael J. Fox Foundation, with ARUK as a funding partner. Awards last up to 12 months, and successful applicants are expected to start work within six weeks of the award being issued.
About the dataset
UKB-PRISM uses the Alamar NULISA Neuro 220 proteomics platform and covers around 80,000 samples: up to 75,000 baseline samples and up to 5,000 longitudinal samples. It includes imaging data for about 50,000 participants, and roughly 3,400 dementia cases, 300 FTD cases and 5,200 parkinsonism cases. If you’re new to working with this kind of resource, our piece on enabling dementia research using UK Biobank and our webinar on decoding neurodegeneration with proteomics are good places to start.
What the award will fund
The call is open to biological, clinical, epidemiological, computational, statistical, translational and methodological research. Projects might aim to deliver biological insights, new analytical methods, a better understanding of disease mechanisms, risk prediction, patient stratification, therapeutic development, or tools and resources for the wider community.
ARUK particularly encourages proposals that make the most of the population-scale, longitudinal nature of the data, and that link it with UK Biobank’s genetic, imaging, clinical and lifestyle data.
Who can apply
- The Lead Applicant and any Joint Lead Applicant must be based at a UK university, hospital or research institution.
- Applicants should show expertise in data science, bioinformatics, statistics, machine learning or a related field.
- Successful applicants must be able to meet UK Biobank’s data access requirements (including signing the UK Biobank MTA), ARUK’s award conditions, and any ethical or regulatory requirements.
How applications are assessed
An independent panel will look at how well the project uses UKB-PRISM’s strengths, its novelty and impact, analytical rigour, feasibility, benefit to the wider community, team expertise and open science plans. ARUK makes the final decisions. There is no rebuttal stage, and feedback may be limited.
Funded teams will have a check-in meeting four to six months after their project starts and are expected to report on progress regularly. No-cost extensions are not allowed, and standard ARUK grant conditions apply.
Key dates and how to apply
- Deadline: 12pm (midday), 6 January 2027
- Funding outcome: March 2027
Applications are made through ARUK’s Flexigrant system. The Lead Applicant submits, and the Host Institution’s Organisation Admin must approve the application before the deadline, so build in time for that sign-off. ARUK says it may close the call early if application numbers are higher than expected, so don’t leave it to the last minute.
Read ARUK’s research guidelines, policies and application FAQs before you apply. Questions can go to research@alzheimersresearchuk.org. You can find more opportunities on our funding calls page.
Visit funding web page
(https://www.alzheimersresearchuk.org/grants/data-discovery-award/)
